The application study of rapid on-site evaluation technology guidance in metagenomic next-generation sequencing technology for the diagnosis of suspected pulmonary sarcoidosis
ZHANG Jun-li
ZHANG Zhi-yuan
LIU Qiu-shi
BU Jin-long
LI Bai-ning
MA De-bin
Abstract：Objective To investigate the application value of rapid on-site evaluation (ROSE) to assess whether metagenomics next-generation sequencing (mNGS) is performed in suspected pulmonary sarcoidosis. Methods A total of 96 patients with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) who were found to have hilar and/or mediastinal lymphadenopathy and clinically suspected sarcoidosis by chest computed tomography from January to december 2022 retrospectively analyzed. Among them,42 patients underwent ROSE during surgery and 54 patients without ROSE.The number of puncture needles,mNGS submission rate,mNGS positive rate,proportion of non-diagnostic specimens,and initial disease diagnosis rate of the two groups were analyzed. Results The number of puncture needles of ROSE group was (2.73±1.15) times,which was significantly higher than (2.44±1.06) times of non-rose group,but there was no statistical significance between the two groups (P>0.05). The detection rate of mNGS in ROSE group was 83.3％ (35/42),which was significantly lower than 98.1％(53/54)of non-rose group,and the difference was statistically significant (P<0.05). The proportion of non-qualified specimens in ROSE group was 11.9％ (5/42),which was significantly lower than 31.5％(17/54)of non-rose group,and the difference was statistically significant (P<0.05). The diagnosis rate of ROSE group was 81.0％ (34/42),which was significantly higher than 59.3％(32/54)of non-rose group,and the difference was statistically significant (P<0.05). The positive rate of mNGS in ROSE group was 34.0％ (12/35),which was higher than 26.0％ (14/53) of non-rose group,there was no statistical significance between the two groups (P>0.05). Conclusion In patients with suspected pulmonary sarcoidosis who need to undergo EBUS-TBNA,the application of ROSE to guide whether to submit the samples for mNGS testing can reduce the mNGS submission rate,decrease the proportion of non-compliant specimen,and improve the diagnostic rate.
Keywords：Rapid on-site evaluationMetagenomics next-generation sequencingEndobronchial ultrasound-guided transbronchial needle aspirationSarcoidosis
Publication Date：2024-02-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 41-43,64 )